Ideaya licenses antibody-drug conjugate for cancer treatments

 

• Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
• DLL3 highly expressed in Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), respectively 85% and 20-40%
• Rational combination opportunities with IDEAYA's DNA Damage Repair (DDR) clinical pipeline, including Phase 1 PARG inhibitor IDE161
• Targeting US IND filing for SHR-4849 in H1 2025

https://www.prnewswire.com/news-releases/ideaya-biosciences-enters-exclusive-license-with-hengrui-pharma-for-shr-4849-a-novel-phase-1-dll3-topo-i-payload-adc-targeting-sclc-and-net-solid-tumors-302339847.html